Ontology highlight
ABSTRACT: Background
The HIV reservoir of latently infected CD4+ T cells represents the barrier to cure. CD4+ T-cell proliferation is a mechanism that sustains the reservoir even during prolonged antiretroviral therapy (ART). Blocking proliferation may therefore deplete the reservoir.Methods
We conducted an unblinded, uncontrolled clinical trial of mycophenolate, a T-cell antiproliferative compound, in people with HIV on chronic suppressive ART. Study drug dose selection was based on calibration to an observed ex vivo antiproliferative effect. The primary outcome was clinically significant reduction (>0.25 log10) in the HIV reservoir, measured by total and intact HIV DNA per million T cells in blood over 48 weeks.Results
Five participants enrolled in the trial. Four participa
SUBMITTER: Schiffer JT
PROVIDER: S-EPMC9745781 | biostudies-literature | 2022 Dec
REPOSITORIES: biostudies-literature